跳到正文
原文
STAT 主站· Andrew Joseph·· 3 天前精选AI 评分67

FDA 批准罗氏新乳腺癌药物,为患者提供新选择

STAT+: FDA approves new breast cancer drug, providing new option for some patients, boost for Roche

AI 导读

FDA 批准罗氏的 Wilserdly(giredestrant)用于特定乳腺癌适应症,延长肿瘤进展时间,为患者提供新治疗选择。

推荐理由

FDA 批准新药用于特定乳腺癌适应症,为患者提供新选择。

正文 · 原文

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever.

The approval of Wilserdly, also known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It also gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its subsidiary Genentech, though in recent years it’s fallen behind rival pharma companies in oncology. 

The approval is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments. The evERA trial showed that the drug, an oral treatment known as a selective estrogen receptor degrader, or SERD, extended the time period before patients’ tumors progressed.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT 主站 · statnews.com